Ionis Pharmaceuticals (IONS) - Stock & Dividends

Ionis Pharmaceuticals, Inc., located in Carlsbad, California, focuses on developing specialized RNA-targeted therapeutics within the United States. The company's innovative portfolio includes SPINRAZA, tailored for the treatment of spinal muscular atrophy in both pediatric and adult patients.

In addition to SPINRAZA, Ionis Pharmaceuticals offers TEGSEDI, designed as an antisense injection to address polyneuropathy caused by hereditary transthyretin amyloidosis, primarily in adults. It also provides WAYLIVRA, an antisense medication for treating familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Furthermore, Ionis Pharmaceuticals has an array of advanced medicines in phase 3 trials, such as Eplontersen, Olezarsen, Donidalorsen, ION363, Tofersen, Pelacarsen, and Bepirovirsen, targeting various conditions ranging from cardiovascular disease to hepatitis B virus. Moreover, the company's research involves Cimdelirsen, IONIS-FB-LRx, and ION224, which aim to reduce the production of specific proteins associated with different health issues.

Collaborating with Biogen for neurological disorders and partnering with Metagenomi, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics through various agreements, Ionis Pharmaceuticals continuously strives to advance therapeutic solutions for complex medical conditions.

Established in 1989, Ionis Pharmaceuticals has a long-standing commitment to innovation and improving patients' lives through cutting-edge RNA-targeted therapies. To learn more about the company, visit their official website: https://www.ionispharma.com.